Update Alert 10: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.
作者信息
Mackey Katherine, Kansagara Devan, Vela Kathryn
机构信息
VA Portland Health Care System, Portland, Oregon.
出版信息
Ann Intern Med. 2023 May;176(5):eL230049. doi: 10.7326/L23-0049. Epub 2023 Mar 21.
Abstract
摘要
相似文献
1
Update Alert 10: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.更新警报10：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的风险及影响
Ann Intern Med. 2023 May;176(5):eL230049. doi: 10.7326/L23-0049. Epub 2023 Mar 21.
2
Update Alert 9: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.最新警报9：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对2019冠状病毒病感染的风险及影响
Ann Intern Med. 2022 Apr;175(4):W47-W48. doi: 10.7326/L21-0791. Epub 2022 Feb 8.
3
Update Alert 5: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.最新警报5：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对新型冠状病毒感染的风险及影响
Ann Intern Med. 2020 Dec 15;173(12):167-168. doi: 10.7326/L20-1293. Epub 2020 Oct 27.
4
Update Alert 6: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.更新警报6：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的风险及影响
Ann Intern Med. 2021 Jan;174(1):W17. doi: 10.7326/L20-1355. Epub 2020 Dec 1.
5
Update Alert 4: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.最新警报4：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对新型冠状病毒感染的风险及影响
Ann Intern Med. 2020 Nov 3;173(9):W147-W148. doi: 10.7326/L20-1177. Epub 2020 Sep 22.
6
Update Alert: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.最新警报：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的风险及影响
Ann Intern Med. 2020 Aug 4;173(3):W66. doi: 10.7326/L20-0887. Epub 2020 Jun 25.
7
Update Alert 2: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.最新警报2：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的风险及影响
Ann Intern Med. 2020 Sep 1;173(5):W87. doi: 10.7326/L20-0969. Epub 2020 Jul 23.
8
Update Alert 3: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.更新警报3：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的风险及影响
Ann Intern Med. 2020 Oct 6;173(7):130-131. doi: 10.7326/L20-1068. Epub 2020 Aug 26.
9
Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers benefits outweigh the risks in COVID-19 hypertensive patients.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂对新冠肺炎高血压患者的益处大于风险。
J Med Virol. 2021 Apr;93(4):1873-1874. doi: 10.1002/jmv.26672. Epub 2020 Nov 22.
10
Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review.血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对成人 SARS-CoV-2 感染的风险和影响：一项实时系统评价。
Ann Intern Med. 2020 Aug 4;173(3):195-203. doi: 10.7326/M20-1515. Epub 2020 May 15.
本文引用的文献
1
Ramipril for the Treatment of COVID-19: RAMIC, a Randomized, Double-Blind, Placebo-Controlled Clinical Trial.雷米普利治疗 COVID-19：RAMIC，一项随机、双盲、安慰剂对照临床试验。
Adv Ther. 2023 Nov;40(11):4805-4816. doi: 10.1007/s12325-023-02618-7. Epub 2023 Aug 24.
2
Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial.血管紧张素受体阻滞剂治疗 COVID-19：实用、适应性、多中心、3 期、随机对照试验。
BMJ. 2022 Nov 16;379:e072175. doi: 10.1136/bmj-2022-072175.
3
Renin-Angiotensin System Inhibitors in Patients With COVID-19: A Meta-Analysis of Randomized Controlled Trials Led by the International Society of Hypertension.血管紧张素转化酶抑制剂和血管紧张素受体拮抗剂治疗新型冠状病毒肺炎有效性和安全性的系统评价和 Meta 分析
J Am Heart Assoc. 2022 Sep 6;11(17):e026143. doi: 10.1161/JAHA.122.026143. Epub 2022 Aug 24.
4
COVIDMED - An early pandemic randomized clinical trial of losartan treatment for hospitalized COVID-19 patients.COVIDMED——一项关于氯沙坦治疗住院COVID-19患者的早期大流行随机临床试验。
Contemp Clin Trials Commun. 2022 Oct;29:100968. doi: 10.1016/j.conctc.2022.100968. Epub 2022 Jul 20.
5
Efficacy of Losartan in Hospitalized Patients With COVID-19-Induced Lung Injury: A Randomized Clinical Trial.氯沙坦治疗 COVID-19 相关肺损伤住院患者的疗效：一项随机临床试验。
JAMA Netw Open. 2022 Mar 1;5(3):e222735. doi: 10.1001/jamanetworkopen.2022.2735.
6
Update Alert 9: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.最新警报9：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对2019冠状病毒病感染的风险及影响
Ann Intern Med. 2022 Apr;175(4):W47-W48. doi: 10.7326/L21-0791. Epub 2022 Feb 8.
7
A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19.氯沙坦用于COVID-19有症状门诊患者的多中心II期随机临床试验。
EClinicalMedicine. 2021 Jun 17;37:100957. doi: 10.1016/j.eclinm.2021.100957. eCollection 2021 Jul.
8
Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial.替米沙坦治疗新冠肺炎患者：一项开放的多中心随机临床试验。
EClinicalMedicine. 2021 Jun 18;37:100962. doi: 10.1016/j.eclinm.2021.100962. eCollection 2021 Jul.
9
Randomized Prospective Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized COVID-19 Patients with Mild Hypoxemia.随机前瞻性开放标签研究表明，对轻度低氧血症的住院COVID-19患者加用氯沙坦对临床结局无影响。
Infect Dis Ther. 2021 Sep;10(3):1323-1330. doi: 10.1007/s40121-021-00453-3. Epub 2021 May 11.
10
Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: A randomised clinical trial.比较氯沙坦和氨氯地平对 COVID-19 合并原发性高血压患者结局的影响：一项随机临床试验。
Int J Clin Pract. 2021 Jun;75(6):e14124. doi: 10.1111/ijcp.14124. Epub 2021 Mar 13.
Zotero 插件